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Dear Editor,
We documented a case of a boy with Down’s syndrome in
whom severe haemophilia Awas diagnosed. Haemophilia A
is an inherited, sex-linked disorder in which coagulation
factor VIII (FVIII) is deficient or absent. This disease is
the most frequently diagnosed clotting deficiency in
newborns occurring at about 1 in 5,000–10,000 male births.
Down’s syndrome is a chromosomal condition caused by
the presence of all or part of an extra 21st chromosome
(trisomy 21), and the incidence of the syndrome is estimated
at 1 per 733 births. It is associated with some impairment of
cognitive and physical growth and a particular set of facial
characteristics. Affected individuals tend to have a lower-
than-average cognitive ability, often ranging from moderate
to pronounced disabilities.
The patient was a first child born to young parents. His
uncle from his mothers’ side also suffered from severe
haemophilia A. There were no noted complications during
pregnancy and he was delivered in full term. At birth it was
noted that the patient presented characteristics of Down’s
syndrome. After the administration of hepatitis B vaccina-
tion, the patient developed a massive left thigh muscle
haematoma. Moreover, he was diagnosed with an atrioven-
tricular canal (AVC/AVSD). His activated partial thrombo-
plastin time was 113 s (reference value 28–36 s) and factor
VIII concentration was 0.25 %. Due to the femoral haema-
toma plasma-derived factor VIII, 30 IU per kg was admin-
istered for three consecutive days with improvement. The
molecular analysis of haemophilia mutation was not avail-
able at the time and karyotype analysis confirmed Down’s
syndrome. At 3 months, the boy underwent cardiosurgery
without any complications, under plasma-derived FVIII
protection. He received a dosage of 50 IU per kg in the first
3 days (including the day the surgery was performed), 40 IU
per kg in the next three consecutive days and 30 IU per kg
up to the 14th day after surgery with good hemostasis.
He was on-demand plasma-derived FVIII therapy for
first 3 years of his life. During that period, he had nine
incidents of soft tissue bleeding after slight injuries (gum,
calf, chest muscles). The dosage of factor VIII concentrate
was 2,400 IU per year. At the age of 3, after his first episode
of hip joint bleeding, he started prophylaxis with plasma-
derived factor VIII but due to limitation of FVIII prophy-
laxis accessibility in our country, therapy was halted after
2 months of administration. During the on-demand therapy
which was administrated till he was 5 years, the boy pre-
sented with eight incidents of joint bleeding (hip, knee,
ankle). The dosage of FVIII was 11,500 IU per a year.
Ultimately the boy restarted prophylaxis at the age of 5
when national haemophiliacs plasma-derived FVIII prophy-
laxis programme started in our country. On the primary dose
of 20 IU per kg twice a week, a knee bleeding was noted and
the dosage was increased to 40 IU per kg three times
weekly. In 3 years of high-dose prophylaxis, he did not have
any incidents of joint or soft tissue bleeding. Regular tests
excluded development of FVIII inhibitor.
Currently at age of 8, the patient is still continuing with
prophylaxis. He attends school activities and participates in
rehabilitation exercises.
Clinical and numerous other studies of haemophiliacs
demonstrate that primary prophylaxis is much superior to
on-demand treatment [1–3]. Unfortunately, prophylaxis ac-
cessibility in many health services is limited.
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We presented management of a boy with Down’s syn-
drome and severe haemophilia A. Replacement of FVIII
provided successful concomitant heart defect cardiosurgery
[4]. Due to our national health programme, the boy was on-
demand plasma-derived FVIII therapy. For the first 2 years, he
had a few symptoms due to delayed crawling, inability to walk
and great parental overprotectiveness. Frequency of bleeding
incidences increased with time as he became more active. At
age of 5 he was entered into the national health prophylaxis
programme. The decision to start him on this regimen was
discussed with the patient’s psychologist in order to decide
whether both the patient and his parents would cope with
regular injections. Home therapy was found to be feasible
due to appreciable parental commitment. The administration
of high-dose secondary prophylaxis resulted in marked im-
provement with no bleeding episodes noted. Regardless of the
fact that secondary prophylaxis was delayed, the benefit of the
regimen used in a handicapped boy was unquestionable.
To our knowledge, this is the second case in the available
literature, describing the association of haemophilia A and
Down’s syndrome [5] and the first report of a prophylaxis
regimen in coexistence of these two diseases.
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